Close Menu

CRUK

Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK. 

ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).

CRUK Announces Cuts

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Researchers combined imaging mass spectrometry and genomic data to identify the cell types present in more than 480 breast cancer samples.

The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.

Researchers from the TRACERx consortium analyzed blood and tumor samples to tease out features of lung cancers that are more likely to recur.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.

Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.

Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.